$GTM

ZoomInfo (GTM) Launches Native App Inside OpenAI Codex for Work

ZoomInfo said OpenAI made ZoomInfo natively available inside OpenAI Codex for Work, a B2B data and go-to-market intelligence app. ZoomInfo stated OpenAI selected it to bring verified company intelligence, contacts, and go-to-market signals into Codex so users can run its skills via natural language. Separately, analysts at Morgan Stanley and JPMorgan cut price targets after lower free cash flow and fiscal 2026 outlook.

Original reporting
Published Jun 8, 2026, 7:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 8:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ZoomInfo (GTM) Launches Native App Inside OpenAI Codex for Work — source image
Decision brief

The 30-second read

$GTMBullishMed
01

Why it matters

If Codex users adopt ZoomInfo skills in natural-language workflows, it can increase engagement and conversion for ZoomInfo’s GTM intelligence platform; however, the article also references recent outlook/guidance pressure that could limit valuation expansion.

02

Market read

A concrete AI-distribution update for ZoomInfo (native Codex app) is the main catalyst, but the article also surfaces recent analyst caution tied to FY26 guide cuts and weaker near-term demand indicators.

03

What to watch

The article pairs the product launch with analyst price-target cuts citing lower free cash flow, negative near-term RPO/billings, and softer upmarket expansion—these fundamentals may dominate near-term trading despite the AI integration headline.

Relevance 8/10Novelty 8/10Timing: today / pre-market context (published 2026-06-08)

Background

OpenAI Codex for Work is positioned as an AI work assistant; ZoomInfo is integrating its verified company intelligence, contacts, and go-to-market signals as a native app.

Company-level read

Ticker impact

$GTMBullishMedium confidence
Context

ZoomInfo says OpenAI made ZoomInfo natively available inside OpenAI Codex for Work, embedding its B2B data and skills into Codex workflows.

Expected impact

Near-term upside bias as AI workflow integration can expand customer acquisition and usage; magnitude likely tempered by the article’s concurrent analyst caution on cash flow/RPO.

Evidence & confidence

The article provides a concrete product/distribution update (native Codex app) but also includes recent analyst target cuts tied to weaker FY26 fundamentals, which can cap the immediate multiple expansion.

Market effects

Highlights a growing pattern of CRM/GTM data providers integrating into AI copilots, potentially increasing competitive intensity for B2B data distribution.

No specific regional impact beyond US-listed software/data providers.

Codex-for-Work integration is globally relevant for enterprise go-to-market workflows, but the article provides no geography-specific adoption data.

Counterpoint

Codex integration may be more of a channel/packaging change than a near-term revenue driver, especially if enterprise adoption cycles are slow.

Key entities

  • ZoomInfo Technologies Inc.

    GTM provides go-to-market intelligence and engagement for sales, marketing, operations, and recruiting.

  • OpenAI

    Announced native availability of ZoomInfo inside OpenAI Codex for Work.

  • OpenAI Codex for Work

    AI work assistant where users can add ZoomInfo and run its skills in natural language.

Related articles

$GTMMed

GTM Q2 Deep Dive: Upmarket Focus and Hybrid Pricing Strategy Take Center Stage

ZoomInfo (NASDAQ:GTM) reported Q2 CY2026 revenue of $310.4 million, up 1.2% year over year, beating expectations. Midpoint Q3 revenue guidance was $299.5 million, 1.6% above estimates. Non-GAAP EPS was $0.28, 5.8% above consensus. Management cited upmarket growth, 20% growth in its operations/data business, and a transition to hybrid consumption-based pricing plus AI products like GTM.AI.

$GTMMed

Year Outlook Slightly Exceeds Expectations

ZoomInfo (NASDAQ: GTM) reported Q2 CY2026 revenue of $310.4 million, up 1.2% year on year, beating Wall Street expectations. Next-quarter revenue guidance had a $299.5 million midpoint, 1.6% above estimates. Non-GAAP EPS was $0.28, 5.8% above consensus. The article also cites billings of $295.8 million and 1,891 enterprise customers.

$GTMHigh

ZoomInfo Announces Second Quarter 2026 Financial Results

ZoomInfo Technologies Inc. (GTM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ZoomInfo Announces Second Quarter 2026 Financial Results VANCOUVER, Wash. , August 5, 2026 - ZoomInfo (NASDAQ: GTM), the all-in-one AI GTM platform, today announced its financial results for the second quarter ended June 30, 2026. “Our native MCP integrations with An

$GTMMedAI 9/10

Is ZoomInfo Technologies Inc. (GTM) One of the Best Tech Stocks Under $5 to Buy?

Jefferies downgraded ZoomInfo (GTM) to Hold from Buy on May 21, cutting its price target to $4 from $12 and citing a “material” reduction in projected 2026 revenue growth plus no improvement expected in 2027. The firm said client demand has been weak for two years and AI is changing purchasing behavior. Morgan Stanley on May 19 cut its target to $5 from $9, keeping Equal Weight.

$GKOSMedAI 8/10

Glaukos' Epioxa Shows Durable Benefits At Three Years In Keratoconus Study

Glaukos (GKOS) reported positive three-year data from a Phase 3 extension study of Epioxa, its corneal cross-linking therapy for keratoconus. The study showed durable efficacy and a favorable safety profile, with treated eyes showing sustained improvement in corneal curvature and visual acuity. GKOS reported a narrowed net loss and 50% sales growth in Q2 2026, with 2026 net sales guidance of $680M-$700M. The stock is up 6.55% on the day.

$ADXNMedAI 8/10

Addex Therapeutics: Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia

Addex Therapeutics (ADXN) announced its spin-out, Neurosterix, completed Phase 1 trials for NTX-253, a schizophrenia treatment. Neurosterix plans to advance NTX-253 to Phase 2. Addex holds a 20% stake in Neurosterix, which raised $65M in Series A funding. NTX-253 is a positive allosteric modulator of the muscarinic M4 receptor, showing promising preclinical results.